A Phase 1, Open-label, Multicenter, Dose Escalation Study to Evaluate the Safety of a Single Intravitreal Injection of THR-149 for the Treatment of Diabetic Macular Edema (DME)
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2018
At a glance
- Drugs THR 149 (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Sponsors ThromboGenics
- 25 May 2018 According to a Bicycle Therapeutics media release, initial study results are anticipated in mid-2019.
- 25 May 2018 According to a ThromboGenics media release, first patient has been enrolled in this study.
- 25 May 2018 Status changed from not yet recruiting to recruiting, according to a ThromboGenics media release.